Posts filtered by tags: GlaxoSmithKline[x]


 

Flagship Pioneering Unveils Kintai’s Gut Approach to Treating Disease

The gastrointestinal system is often viewed as a barrier to drugs. Conditions ideal for breaking down food also break down drugs in ways that can limit how well they work. Interaction with the gut microbiome can also diminish a drug’s efficacy or boost its toxicity.Paul-Peter Tak, a former GlaxoSmithKline (NYSE: GSK) executive who is now the CEO of Cambridge, MA-based Kintai Therapeutics, contends that the gut and its microflora can also open up new ways to treat an array of diseases throughout...
Tags: Startups, Drugs, Boston, Cancer, Trends, Ulcerative Colitis, Venture Capital, GlaxoSmithKline, Parkinson's Disease, Biotech, Microbiome, Metabolism, Life Sciences, Clinical Trials, GSK, Cambridge MA


Gary Vaynerchuk drops some F bombs on Publicis Media

It wouldn’t be a Gary Vaynerchuk presentation without a few F-bombs. On Friday, he dropped a megaton or so on Publicis Media CEO Steve King and holding companies generally at the Association of National Advertisers Media Leadership Conference in Orlando, evoking audience laughter as he alleged Publicis and other holding company contracts keep clients bound to agencies against their will. This came in response to a question by moderator Benjamin Jankowski, Mastercard senior vice president for ...
Tags: Advertising, GlaxoSmithKline, King, Publicis, Steve, Orlando, Gary Vaynerchuk, GSK, Steve King, Jankowski, VaynerMedia, Publicis Media, Benjamin Jankowski Mastercard, Scott Grenz


U.S., China key to GSK's consumer venture with Pfizer

The United States and China will be key focuses for the consumer healthcare venture being formed by GlaxoSmithKline and Pfizer, as the companies look to build on strong existing positions in those markets.
Tags: Money, China, businessNews, United States, GlaxoSmithKline, Pfizer, GSK


SpringWorks, Armed with Ex-Pfizer Cancer Drugs, Reloads with $125M

SpringWorks Therapeutics, a startup spun out of Pfizer to develop drugs gathering dust on the New York pharma giant’s shelves, has closed its second nine-figure financing round in less than two years.The $125 million Series B funding gives the New York City startup the backing to bring two cancer drugs into what could be their final trials before regulatory approval, if all goes well. Perceptive Advisors led the round, but Springworks also has the backing of two pharma companies—Pfizer (NYSE: P...
Tags: Deals, Startups, New York, New York City, Trends, Vc, Fda, GlaxoSmithKline, Pfizer, Bain Capital, Life Sciences, GSK, OrbiMed Advisors, BeiGene, National blog main, New York blog main


Researchers describe mathematical model as key to developing effective drugs for brain disorders

A collaboration between researchers from the UAB Institute of Neurosciences and the pharmaceutical company GlaxoSmithKline, published in March in Trends in Pharmacological Sciences, describes a mathematical model to quantify the activity of biased G-protein-coupled receptors.
Tags: Health, GlaxoSmithKline, Pharmacological Sciences, UAB Institute of Neurosciences


New mathematical model could be key to designing effective therapies for brain disorders

A collaboration between researchers from the UAB Institute of Neurosciences (INc) and the pharmaceutical company GlaxoSmithKline, published in March in Trends in Pharmacological Sciences, describes a mathematical model to quantify the activity of biased G-protein-coupled receptors.
Tags: GlaxoSmithKline, Pharmacological Sciences, UAB Institute of Neurosciences INc


GSK reports positive data from trial of endometrial cancer drug

GlaxoSmithKline said on Tuesday a study testing its experimental drug dostarlimab in women with recurrent or advanced endometrial cancer showed promising results. Results from the GARNET study showed the drug elicited clinically meaningful and durable response rates when used to treat certain types of tumors, GSK said. GSK said it would apply for marketing approval for dostarlimab in endometrial cancer at the end of 2019.
Tags: Science, GlaxoSmithKline, GSK


Better Buy: GlaxoSmithKline vs. Eli Lilly

Find out which iconic pharmaceutical giant is the better stock pick at the moment.
Tags: Science, GlaxoSmithKline, Eli Lilly


British fraud office abandons Rolls-Royce, GSK investigations

The UK's Serious Fraud Office (SFO) has abandoned two of its largest and longest investigations, into alleged bribery at aero engine maker Rolls-Royce and drugs maker GlaxoSmithKline, in a move described by one lawyer as "extraordinary".
Tags: UK, Money, businessNews, GlaxoSmithKline, Rolls Royce, GSK, Serious Fraud Office SFO


UK's Serious Fraud Office drops probes at Rolls Royce, GSK

Britain's Serious Fraud Office (SFO) has dropped long-running investigations into individuals at aero engine maker Rolls-Royce and drugs giant GlaxoSmithKline, adding to a growing list of cases where the agency has failed to land convictions.
Tags: UK, Money, businessNews, Britain, Serious Fraud Office, GlaxoSmithKline, Serious Fraud Office SFO, Rolls Royce GSK


UK's Serious Fraud Office drops investigations of Rolls Royce individuals, GSK

Britain's Serious Fraud Office (SFO) has dropped its investigations into aero engine maker Rolls-Royce individuals and drugs giant GlaxoSmithKline, citing insufficient evidence.
Tags: UK, Money, businessNews, Britain, Serious Fraud Office, GlaxoSmithKline, GSK, Serious Fraud Office SFO


Passage Bio Gets $116M As Wilson, Yamada Team Up On Gene Therapy Again

Longtime biopharmaceutical executive Tachi Yamada helped keep the work of gene therapy pioneer James Wilson alive 20 years ago when Wilson was mired in controversy and the emerging field was in its darkest days.Now that gene therapy has come of age, in part because of Wilson’s work, the two are teaming up again. They’ve co-founded a startup, Passage Bio, which aims to use the technology to treat a slew of rare brain diseases.Passage, which has a broad alliance with Wilson’s gene therapy center ...
Tags: Deals, Startups, Trends, Vc, Philadelphia, Fda, National, University of Pennsylvania, GlaxoSmithKline, Parkinson's Disease, James Wilson, Life Sciences, Wilson, Clinical Trials, New Leaf Venture Partners, Takeda


23andMe is upending how we find new drugs, and the CEO says 13 are now in early trials

Silicon Valley genetic testing startup 23andMe is making progress in its efforts to develop new drugs for everything from skin conditions to cancer and heart disease, the CEO said at an event last week. Therapeutics with the 23andMe label would be a "source of pride" for the company, she added. 23andMe now has 13 drug candidates in its pipeline with two compounds in the animal testing phase of research. Could 23andMe-branded drugs one day grace the shelves of your medicine cabinet? Anne Wojci...
Tags: Trends, Silicon Valley, GlaxoSmithKline, Bill, Melinda Gates, Wall Street Journal, Anne Wojcicki, Genentech, GSK, Crest, Wojcicki, Alnylam, Richard Scheller, Pfizer Biogen Genentech


AbbVie Joins Myeloma Race with $90M Deal for Rights to Teneobio Drug

AbbVie is paying $90 million up front for rights to a multiple myeloma drug from Teneobio that’s now being prepared for tests in humans.The Teneobio drug, TNB383B, is the first to come out of the labs of the Menlo Park, CA, biotech. Under the deal, AbbVie has the right to develop the drug after it completes Phase 1 testing. AbbVie would pay milestones pegged to the progress of the drug, plus royalties if it reaches the market. Additional details of those payments weren’t disclosed.Teneobio alre...
Tags: Deals, Startups, Drugs, Cancer, San Francisco, Trends, Investing, GlaxoSmithKline, Abbvie, Biotech, Life Sciences, Clinical Trials, Celgene, Amgen, American Cancer Society, Janssen


GSK pays up to $4.2 billion for Merck KGaA cancer immunotherapy

GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday, agreeing to pay up to 3.7 billion euros ($4.2 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy. Merck will receive an upfront payment of 300 million euros for the drug - known as M7824, or bintrafusp alfa - and is eligible for potential payments of up to 500 million euros depending on development milestones in lung cancer, the two companies said in statements on Tuesday. Merck could als...
Tags: Science, Germany, Merck, GlaxoSmithKline, GSK, Merck KGaA


Merck KGaA wins GSK for immunotherapy deal worth up to $4.2 billion

GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday, agreeing to pay up to 3.7 billion euros ($4.22 billion) to Germany's Merck KGaA for the rights to a novel immunotherapy. Merck will receive an upfront payment of 300 million euros for the drug known as M7824 and is eligible for potential payments of up to 500 million euros depending on development milestones in lung cancer, the two companies said in statements on Tuesday. Merck will also be eligible for further paymen...
Tags: Science, Germany, Merck, GlaxoSmithKline, GSK, Merck KGaA


How the finance industry can save the world

For millennia, the finance industry has been a primary culprit in global warming. Now it's time for finance to right its wrongs and provide the solution.It's easy to read about the current and future state of our climate and have a fit of despair. For years, the scientific consensus was that we'd be fine if temperatures increased from pre-industrial levels by less than 2°C. But the UN's recent global warming report revises the threshold, showing that a 1.5°C increase will have catastrophic effec...
Tags: Money, Climate Change, Finance, Environment, US, Unilever, Economics, Sustainability, Innovation, Un, GlaxoSmithKline, Oxford University, Jones, Trump, Myles Allen, Williamson


Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More

Diabetes drugs are Eli Lilly’s bread and butter, but the pharmaceutical giant hasn’t lost its appetite for cancer drugs. It grabbed hold of a few more this week by betting $8 billion on Loxo Oncology.Loxo (NASDAQ: LOXO) has made a name for itself by becoming one of just two companies ever to earn an FDA approval for a drug that targets a tumor’s DNA fingerprint, no matter where in the body that cancer is found. The drug, larotrectinib, targets rare tumor abnormalities known as NTRK fusions. The...
Tags: Deals, Startups, Ipo, Cancer, Trends, Medicare, SEC, Fda, National, GlaxoSmithKline, Allergan, Shire, Biotech, Medical Device, Postpartum Depression, Bernie Sanders


Bio-JPM Roundup: Lilly Buys Loxo, Sage’s Stock Soars, ALS Cash & More

The flow of biotech news is particularly heavy today, and for good reason. The annual J.P. Morgan Healthcare Conference, one of the biggest gatherings for the biopharmaceutical industry, kicked off today in San Francisco, and many companies, whether they’re speaking at the event or not, use this time to get their news out.Xconomy is on the ground covering the conference this week. In the meantime, here’s a short roundup of biotech news announced today.DEALS AND DATA—Eli Lilly (NYSE: LLY) is pay...
Tags: Deals, Startups, San Francisco, Trends, Investing, Vc, Venture Capital, Fda, National, GlaxoSmithKline, Biotech, Postpartum Depression, Life Sciences, Clinical Trials, Celgene, Gilead Sciences


Eli Lilly Makes an $8B Cancer Genetics Bet with Loxo Acquisition

[Updated 1/7/19, 11 a.m. ET. See below.] Eli Lilly is set to acquire Loxo Oncology for approximately $8 billion—a deal that brings to the Indianapolis pharmaceutical giant a class of drugs that treat cancers with particular genetic signatures.Under the agreement announced Monday, Lilly (NYSE: LLY) will pay $235 cash per share of Loxo (NASDAQ: LOXO), which is a 68 percent premium to the Friday closing price of the Stamford, CT, cancer drug developer. Following the news of the deal, shares of Lox...
Tags: Deals, Drugs, Cancer, Trends, Indiana, Indianapolis, Mergers and Acquisitions, Fda, GlaxoSmithKline, Biotech, Life Sciences, Bayer, Clinical Trials, Celgene, American Society of Clinical Oncology, Stamford


Genetic testing could be the future of healthcare, but some doctors think companies like 23andMe might be doing more harm than good

Genetic testing will be a cornerstone of healthcare in 2019, experts say. There are two ways to do the testing: getting a costly but complete genetic workup through a doctor or opting for a cheaper at-home test like those sold by 23andMe. Clinicians and advocates criticize the at-home approach, which they say prioritizes and long-term health. But entrepreneurs counter that the at-home approach lets more people access information. Which method will win out, and at what cost? As millions of A...
Tags: Google, Trends, Food And Drug Administration, Helix, Fda, GlaxoSmithKline, Barry, Ross, 23andMe, Luna, Rogers, Anne Wojcicki, Ancestry, Hazel, Vanderbilt University, Levin


Genetic testing is the future of healthcare, but many experts say companies like 23andMe are doing more harm than good

Genetic testing will be a cornerstone of healthcare in 2019, experts say. There are two ways to do the testing: getting a costly but complete genetic workup through a doctor or opting for a cheaper at-home test like those sold by 23andMe. Clinicians and advocates criticize the at-home approach, which they say prioritizes and long-term health. But entrepreneurs counter that the at-home approach lets more people access information. Which method will win out, and at what cost? As millions of A...
Tags: Google, Trends, Food And Drug Administration, Helix, Fda, GlaxoSmithKline, Barry, Ross, 23andMe, Luna, Rogers, Anne Wojcicki, Ancestry, Hazel, Vanderbilt University, Levin


Genetic Info is Less Valuable Than Social and Search Data

GlaxoSmithKline has invested $300 million into 23andMe. GSK and 23andMe will partner to develop new medicines. They will split costs and profits equally. 23andMe raised $250 million at a $1.75... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Tags: Innovation, GlaxoSmithKline, GSK, Search Data


How to Save $650 Million Without Really Trying

Pfizer and GlaxoSmithKline join forces with their consumer healthcare businesses, creating plenty of synergies.
Tags: Finance, Article, GlaxoSmithKline, Pfizer, FBN, Motley Fool, Fbn/markets, Fox-business/markets, 6c7b5bc0-762d-505d-b604-56a7a009043d


5 things to know about DNA tests before you send your spit

This Christmas, plenty of people will find DNA tests under the tree.  They're easy to use — just send 23andMe, Ancestry, or one of their competitors your spit, and in exchange you're promised a detailed breakdown of your heritage. For a little extra cash, you can learn about your genetic health risks, too.  23andMe and Ancestry are privately held companies that don't disclose sales numbers. But ads for them are all over the internet these days. Last year, Ancestry claimed it sold ...
Tags: Asia, England, Science, Africa, Bloomberg, Philippines, Italy, Denmark, Npr, GlaxoSmithKline, Ancestry, U S Food and Drug Administration, Golden State Killer


GlaxoSmithKline and General Mills climb while FedEx drops

NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday:FedEx Corp., down $22.50 to $162.51The shipping company said international shipping dropped in the last quarter.GlaxoSmithKline PLC, up 31 cents to... [Author: [email protected]]
Tags: Business, New York, Ap, GlaxoSmithKline, General Mills, FedEx Corp, GlaxoSmithKline Plc


Markets Right Now: Stocks move higher as oil price rebounds

NEW YORK (AP) — The latest on developments in financial markets (all times local):11:45 a.m.Stocks are higher on Wall Street as energy companies benefit from a partial recovery in oil prices following a huge loss the day before.GlaxoSmithKline... [Author: [email protected]]
Tags: Business, New York, GlaxoSmithKline


GlaxoSmithKline and Pfizer to Merge Consumer Health Units

The companies say their new venture will be the world’s largest maker of over-the-counter products like pain relievers, toothpastes, cold treatments, vitamins and dietary supplements.
Tags: News, United States, Mergers, GlaxoSmithKline, Pfizer, Great Britain, Pfizer Inc, GlaxoSmithKline Plc, Acquisitions and Divestitures, Vitamins, Dietary Supplements and Herbal Remedies, Drugs (Pharmaceuticals


Pfizer, GSK to Merge Consumer Health Units, Focus on Prescription Drugs

Two of the world’s top drugmakers want to focus on making prescription drugs. Pfizer and GlaxoSmithKline have agreed to merge their consumer health businesses and spin them off into a joint venture, a move that will both create a new consumer healthcare giant and increase the pressure on each company to churn out innovative medicines.GSK (NYSE: GSK) will hold 68 percent of the new company, with Pfizer (NYSE: PFE) getting the remaining 32 percent. The combined company will have some $12.7 billio...
Tags: Deals, Drugs, Trends, National, GlaxoSmithKline, Novartis, Pfizer, Vaccines, Pharma, Life Sciences, GSK, National blog main, New York blog main, Seattle blog main, Boston blog main, National top stories


GSK, Pfizer to merge health care divisions

LONDON (AP) — Drugmakers GlaxoSmithKline and Pfizer are merging their health care divisions, creating a market leader in "over the counter" health care products like pain relievers and vitamins with combined sales of 9.8 billion pounds... [Author: [email protected]]
Tags: Business, London, Ap, GlaxoSmithKline, Pfizer, GSK Pfizer